RCUS Stock: Price, Earnings History and SEC Filings
Arcus Biosciences, Inc. (RCUS) last traded at $18.19, down 2.26% on the latest session and down 29.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.72 against an analyst estimate of $-0.98, a beat of 26.5%.
$18.19 -2.26%
1 month-29.58%
52-week high$31.74
52-week low$17.43
Volume1.94M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RCUS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.72 | $-0.98 | +26.53% |
| Mar 2026 | May 5, 2026 | $-1.02 | $-0.92 | -10.87% |
| Dec 2025 | Feb 25, 2026 | $-0.89 | $-1.11 | +19.82% |
| Sep 2025 | Oct 28, 2025 | $-1.27 | $-1.33 | +4.51% |
RCUS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RCUS
SEC filing data is not available right now. You can search for RCUS on SEC EDGAR.
RCUS news
- Arcus Biosciences Announces New Employment Inducement GrantsOct 26, 2026 · finance.yahoo.com
- How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share SaleOct 24, 2026 · finance.yahoo.com
- Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data ImpressesOct 24, 2026 · finance.yahoo.com
- Arcus Biosciences Completes $269 Million Common Stock OfferingOct 24, 2026 · theglobeandmail.com
- Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockOct 22, 2026 · finance.yahoo.com
- Arcus Biosciences stock falls on public offering announcementOct 21, 2026 · finance.yahoo.com
- Arcus Biosciences Announces Commencement of Public Offering of Common StockOct 21, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) is a US-listed public company on NYSE.